Philip Q Ding
Overview
Explore the profile of Philip Q Ding including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee C, Freeman M, Burak K, Moffat G, ODonnell C, Ding P, et al.
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199649
The IMbrave150 trial established atezolizumab with bevacizumab (A+B) as standard care for hepatocellular carcinoma (HCC), recommending an esophagogastroduodenoscopy (EGD) within 6 months of treatment initiation to prevent bleeding from esophagogastric...
2.
Lim C, Amaro C, Ding P, Cheung W, Tam V
Cancer Med
. 2024 Jul;
13(13):e7415.
PMID: 38953381
Background: Lenvatinib (LEN) and atezolizumab + bevacizumab (A + B) have drastically changed the treatment paradigm for advanced hepatocellular carcinoma (HCC). Before these landmark trials, sorafenib (SOR) served as the...
3.
Samnani S, Ding P, Lee-Ying R, Cheung W, Karim S
JCO Oncol Pract
. 2024 Jun;
20(12):1629-1636.
PMID: 38913969
Purpose: The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration showed no significant clinical difference in outcomes in patients with stage III colon cancer (CC) treated with 3 versus 6...
4.
Woo T, Stukalin I, Ding P, Goutam S, Sander M, Ewanchuk B, et al.
Curr Oncol
. 2023 Oct;
30(10):8936-8947.
PMID: 37887546
: The majority of melanoma is diagnosed in individuals between 55 and 84 years old. Current data varied in reporting differences in survival outcomes amongst different age groups. A retrospective,...
5.
Yun J, Ding P, Dolley A, Cheung W
Curr Oncol
. 2023 Sep;
30(9):8005-8018.
PMID: 37754496
The management of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is limited and remains an unmet need. Decitabine/cedazuridine (DEC-C, ASTX727) is Canada's first and only approved oral hypomethylating agent...
6.
Rigo R, Ding P, Batuyong E, Cheung W, Walker J, Monzon J, et al.
Oncologist
. 2023 Aug;
29(1):57-66.
PMID: 37648247
Background: Adjuvant therapies have been approved for resected melanoma based on improved recurrence-free survival. We present early findings from a real-world study on adjuvant treatments for melanoma. Methods: A comprehensive...
7.
Ding P, Au F, Cheung W, Heitman S, Lee-Ying R
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627149
Surveillance of stage IV colorectal cancer (CRC) after curative-intent metastasectomy can be effective for detecting asymptomatic recurrence. Guidelines for various forms of surveillance exist but are supported by limited evidence....
8.
Ding P, Dolley A, Cheung W
Curr Oncol
. 2023 Jan;
30(1):130-144.
PMID: 36661660
Background: Gastric cancer mortality remains among the highest of all cancers. Trifluridine/tipiracil (FTD/TPI) represents Canada's first standard-of-care, third-line, systemic therapy for metastatic gastric/gastroesophageal cancer. We characterized real-world treatment patterns in...
9.
Ding P, Newcomer B, Cheung W
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551681
Background: There are limited published data in the Canadian healthcare system on the use of granulocyte colony-stimulating factor (G-CSF) among patients with breast cancer. This study characterized real-world G-CSF use...
10.
Breadner D, Loree J, Cheung W, Gipson M, Lakkunarajah S, Mulder K, et al.
BMC Cancer
. 2022 Nov;
22(1):1119.
PMID: 36319973
Background: Colorectal cancer remains the second leading cause of cancer death in North America. Fluorouracil and oxaliplatin based adjuvant chemotherapy for resected colon cancer (CC) reduces cancer recurrence, but also...